Medical/Pharmaceuticals

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment ofJohn Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the developme...

2021-11-16 00:00 1879

EDAN Revealed Its Blueprint on Speeding Up Clinic Workflow at MEDICA 2021

DUSSELDORF, Germany, Nov. 15, 2021 /PRNewswire/ -- EDAN Instruments, Inc. (300206.SZ), a leading healthcare company in the field of Obstetrics and Gynecology, Diagnostic ECG, Patient Monitoring, Ultrasound Imaging, andIn-Vitro Diagnostics, re-emphasis its value proposition ...

2021-11-15 23:15 1787

CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted Priority M...

2021-11-15 22:10 4995

Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO Gastrointestinal Cancers Symposium

TAIPEI and SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting clinical design for their lead drug candidate...

2021-11-15 20:00 1476

Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention

JIUQUAN, China, Nov. 15, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI

2021-11-15 20:00 1282

CBC Group Partners with APG to Launch Healthcare Real Estate Platform and Announce US$500 Million First Close of China Life Science Venture

SHANGHAI, Nov. 14, 2021 /PRNewswire/ --CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm, announced today a partnership with APG Asset Management ("APG"), the largest pension provider inthe Netherlands, in a newAsia-Pacific healthcare platform, CBC Healthcare Infrastructure P...

2021-11-15 10:08 2475

InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA

BEIJING, Nov. 14, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 by the US Food and Drug A...

2021-11-15 08:30 1701

$5M Boost to Innovation in Australia with New Illumina Genomics Lab

New laboratory opens in Melbourne Biomedical Precinct to accelerate the adoption of genomics in healthcare and agriculture inAustralia. MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), the global leader in genomics, today announced the opening of a new, fully eq...

2021-11-15 06:14 6097

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...

2021-11-13 05:30 4624

Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China

SUZHOU, China, Nov. 12, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical ...

2021-11-12 14:17 1735

InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development

BEIJING, Nov. 12, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Goldman Sachs and Morgan Stanley to share company's latest development. Details are as follows: ...

2021-11-12 14:14 1591

Planet Innovation acquires BIT Group's North American operations, doubling its medtech manufacturing capacity

MELBOURNE, Australia, Nov. 11, 2021 /PRNewswire/ -- Planet Innovation (PI) has acquired the North American operations of global regulated medical device manufacturer, BIT Analytical Instruments GmbH. The acquisition solidifies PI's commitment to grow its US manufacturing capabilities to suppor...

2021-11-12 07:44 1915

Tabernacle Health Group Launches Revolutionary Immunity Booster. Natural Health Supplement Avrocil (TM) Treats Cold and Flu Symptoms caused by Upper Respiratory Tract Infections

SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- The pandemic sped up participation in virtual exercise classes acrossthe United States, as countless fitness enthusiasts switched to indoor workouts to avoid viruses, such as those that lead to accelerated upper respiratory tract infections, whose sympto...

2021-11-12 02:00 1743

Patients benefited from telemedicine during COVID-19, says new white paper from Healint

* Longitudinal surveys conducted via HeRO™, Healint's proprietary real-world patient insights platform, reveal that 84% would choose telemedicine if it was available, with a preference for follow-up consultations * A 9-month follow-up questionnaire was sent to evaluate changes in patients' ex...

2021-11-11 23:15 1800

Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting

-  Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be  demonstrated during the event in booth #423 -  One immunotherapy combination study adds significant evidence for the potential value of using Lunit SCOPE IO in clinical practice to predict patient res...

2021-11-11 23:00 1455

PNOC Study in Childhood Brain Cancer Enrols First Patient

SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at theUniversity of Calif...

2021-11-11 21:00 2716

Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose

HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose, placeab...

2021-11-11 18:00 1242

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

* Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). * Dosimetry data is be...

2021-11-10 22:06 1762

IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021

SAN JOSE, Calif., NANJING, China and SHANGHAI, Nov. 10, 2021 /PRNewswire/ -- IASO Biotherapeutics("IASO Bio") , a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines, today announced that the updated data fro...

2021-11-10 21:30 1649

I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa

* The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa * Jumpcan will pay I-Mab for a total of up to RMB 2.016...

2021-11-10 17:30 1750
1 ... 152153154155156157158 ... 215